Korean J Pain.  2024 Jul;37(3):247-255. 10.3344/kjp.24046.

Persistent headache and chronic daily headache after COVID-19: a prospective cohort study

• Carvalho LCLS
• Silva PAd
• Rocha-Filho PAS

• KMID: 2557728
• DOI: http://doi.org/10.3344/kjp.24046

Abstract

Background
Little is known about the frequency and impact of the persistent headache and about the incidence of chronic daily headache (CDH) after coronavirus disease 2019 (COVID-19). The aim of this prospective cohort study was to assess the incidence, risk factors, characteristics, and impact of CDH in patients with COVID-19.
Methods
In the first stage, 288 patients were interviewed by telephone after the acute phase of COVID-19. Subsequently, 199 patients who presented headache were reinterviewed at least one year after COVID-19. Headaches that persisted beyond the acute phase of COVID-19 for three or more months and presented frequency ≥ 45 days over the first three months were considered to be CDH.
Results
One hundred and twenty-three patients were included, 56% were females; median age: 50 years (25th and 75th percentile: 41;58). The headache persisted beyond the acute phase of COVID-19 in 52%, and 20.3% had CDH (95% confidence interval: 13.6–28.2). Individuals who previously had headaches and who had headaches of greater intensity during the acute phase were at higher risk of developing CDH. The group with CDH included more females, greater impact of headache, more persistence of headache beyond the 120th day of COVID-19 and less throbbing headache than did the other individuals whose headache persisted.
Conclusions
Patients who had COVID-19 had a high incidence of CDH. Previous headache and greater intensity of headache were associated with higher risk of CDH.

Keyword

COVID-19; Headache; Headache Disorders, Secondary; New Daily Persistent Headache; Pain; PostAcute COVID-19 Syndrome; Prospective Studies; Risk Factors

Reference

1. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. 2021; More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 11:16144. DOI: 10.1038/s41598-021-95565-8. PMID: 34373540. PMCID: PMC8352980.

2. Premraj L, Kannapadi NV, Briggs J, Seal SM, Battaglini D, Fanning J, et al. 2022; Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 434:120162. DOI: 10.1016/j.jns.2022.120162. PMID: 35121209. PMCID: PMC8798975.

3. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. 2021; Attributes and predictors of long COVID. Nat Med. 27:626–31. Erratum in: Nat Med 2021; 27: 1116. DOI: 10.1038/s41591-021-01361-2. PMID: 34045738.

4. Nasserie T, Hittle M, Goodman SN. 2021; Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 4:e2111417. DOI: 10.1001/jamanetworkopen.2021.11417. PMID: 34037731. PMCID: PMC8155823.

5. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. 2022; Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 226:1593–607. DOI: 10.1093/infdis/jiac136. PMID: 35429399. PMCID: PMC9047189.

6. Venkatesan P. 2021; NICE guideline on long COVID. Lancet Respir Med. 9:129. DOI: 10.1016/S2213-2600(21)00031-X. PMID: 33453162.

7. Shanthanna H, Nelson AM, Kissoon N, Narouze S. 2022; The COVID-19 pandemic and its consequences for chronic pain: a narrative review. Anaesthesia. 77:1039–50. DOI: 10.1111/anae.15801. PMID: 35848380. PMCID: PMC9350079.

8. Kim N, Kim J, Yang BR, Hahm BJ. 2022; Associations of unspecified pain, idiopathic pain and COVID-19 in South Korea: a nationwide cohort study. Korean J Pain. 35:458–67. DOI: 10.3344/kjp.2022.35.4.458. PMID: 36175345. PMCID: PMC9530679.

9. Sampaio Rocha-Filho PA. 2022; Headache associated with COVID-19: epidemiology, characteristics, pathophysiology, and management. Headache. 62:650–6. DOI: 10.1111/head.14319. PMID: 35545780. PMCID: PMC9348060.

10. Rocha-Filho PAS, Magalhães JE. 2020; Headache associated with COVID-19: frequency, characteristics and association with anosmia and ageusia. Cephalalgia. 40:1443–51. DOI: 10.1177/0333102420966770. PMID: 33146035. PMCID: PMC7645592.

11. Sampaio Rocha-Filho PA, Magalhães JE, Fernandes Silva D, Carvalho Soares M, Marenga Arruda Buarque L, Dandara Pereira Gama M, et al. 2022; Neurological manifestations as prognostic factors in COVID-19: a retrospective cohort study. Acta Neurol Belg. 122:725–33. DOI: 10.1007/s13760-021-01851-7. PMID: 35060095. PMCID: PMC8776373.

12. Fernández-de-Las-Peñas C, Navarro-Santana M, Gómez-Mayordomo V, Cuadrado ML, García-Azorín D, Arendt-Nielsen L, et al. 2021; Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: a meta-analysis of the current literature. Eur J Neurol. 28:3820–5. DOI: 10.1111/ene.15040. PMID: 34327787. PMCID: PMC8444899.

13. Fernández-de-Las-Peñas C, Cuadrado ML, Gómez-Mayordomo V, Torres-Macho J, Pellicer-Valero OJ, Martín-Guerrero JD, et al. 2022; Headache as a COVID-19 onset symptom and post-COVID-19 symptom in hospitalized COVID-19 survivors infected with the Wuhan, Alpha, or Delta SARS-CoV-2 variants. Headache. 62:1148–52. DOI: 10.1111/head.14398. PMID: 36111527. PMCID: PMC9538062.

14. Nersesjan V, Amiri M, Lebech AM, Roed C, Mens H, Russell L, et al. 2021; Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up. J Neurol. 268:3086–104. DOI: 10.1007/s00415-020-10380-x. PMID: 33438076. PMCID: PMC7803470.

15. Akıncı T. 2023; Post-discharge persistent headache and smell or taste dysfunction after hospitalisation for COVID-19: a single-centre study. Ir J Med Sci. 192:369–75. DOI: 10.1007/s11845-022-02980-5. PMID: 35304709. PMCID: PMC8933127.

16. Ali M. 2022; Severe acute respiratory syndrome coronavirus 2 infection altered the factors associated with headache: evidence from a multicenter community-based case-control study. Pain Rep. 7:e1051. DOI: 10.1097/PR9.0000000000001051. PMID: 36447953. PMCID: PMC9699507.

17. Collantes MEV, Espiritu AI, Sy MCC, Anlacan VMM, Jamora RDG. 2021; Neurological manifestations in COVID-19 infection: a systematic review and meta-analysis. Can J Neurol Sci. 48:66–76. DOI: 10.1017/cjn.2020.146. PMID: 32665054. PMCID: PMC7492583.

18. Rodríguez-Pérez MP, Sánchez-Herrera-Baeza P, Rodríguez-Ledo P, Serrada-Tejeda S, García-Bravo C, Pérez-de-Heredia-Torres M. 2022; Headaches and dizziness as disabling, persistent symptoms in patients with long COVID-A national multicentre study. J Clin Med. 11:5904. DOI: 10.3390/jcm11195904. PMID: 36233769. PMCID: PMC9572453.

19. Garcia-Azorin D, Layos-Romero A, Porta-Etessam J, Membrilla JA, Caronna E, Gonzalez-Martinez A, et al. 2022; Post-COVID-19 persistent headache: a multicentric 9-months follow-up study of 905 patients. Cephalalgia. 42:804–9. DOI: 10.1177/03331024211068074. PMID: 35166156.

20. Sampaio Rocha-Filho PA, Albuquerque PM, Carvalho LCLS, Dandara Pereira Gama M, Magalhães JE. 2022; Headache, anosmia, ageusia and other neurological symptoms in COVID-19: a cross-sectional study. J Headache Pain. 23:2. DOI: 10.1186/s10194-021-01367-8. PMID: 34979899. PMCID: PMC8721484.

21. Mattos ACMT, Souza JA, Moreira PF Filho, Jurno ME, Velarde LGC. 2017; ID-Migraine™ questionnaire and accurate diagnosis of migraine. Arq Neuropsiquiatr. 75:446–50. DOI: 10.1590/0004-282x20170069. PMID: 28746431.

22. Martin M, Blaisdell B, Kwong JW, Bjorner JB. 2004; The Short-Form Headache Impact Test (HIT-6) was psychometrically equivalent in nine languages. J Clin Epidemiol. 57:1271–8. DOI: 10.1016/j.jclinepi.2004.05.004. PMID: 15617953.

23. Caronna E, Ballvé A, Llauradó A, Gallardo VJ, Ariton DM, Lallana S, et al. 2020; Headache: a striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution. Cephalalgia. 40:1410–21. DOI: 10.1177/0333102420965157. PMID: 33146036. PMCID: PMC7645597.

24. Sampaio Rocha-Filho PA. 2024; Headache associated with coronavirus disease 2019. Neurol Clin. 42:507–20. DOI: 10.1016/j.ncl.2023.12.006. PMID: 38575263.

25. Headache Classification Committee of the International Headache Society (IHS). 2018; The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 38:1–211. DOI: 10.1177/0333102417738202.

26. Sousa Melo E, Pedrosa RP, Carrilho Aguiar F, Valente LM, Sampaio Rocha-Filho PA. 2022; Dialysis headache: characteristics, impact and cerebrovascular evaluation. Arq Neuropsiquiatr. 80:129–36. DOI: 10.1590/0004-282x-anp-2021-0133. PMID: 35352752. PMCID: PMC9648914.

27. Oliveira FAA, Sampaio Rocha-Filho PA. 2019; Headaches attributed to ischemic stroke and transient ischemic attack. Headache. 59:469–76. DOI: 10.1111/head.13478. PMID: 30667047.

28. Rocha-Filho PA. 2015; Post-craniotomy headache: a clinical view with a focus on the persistent form. Headache. 55:733–8. DOI: 10.1111/head.12563. PMID: 25903913.

29. Rocha-Filho PA, Gherpelli JL, de Siqueira JT, Rabello GD. 2008; Post-craniotomy headache: characteristics, behaviour and effect on quality of life in patients operated for treatment of supratentorial intracranial aneurysms. Cephalalgia. 28:41–8. DOI: 10.1111/j.1468-2982.2007.01465.x. PMID: 17986272.

30. Rocha-Filho PA, Gherpelli JL, de Siqueira JT, Rabello GD. 2010; Post-craniotomy headache: a proposed revision of IHS diagnostic criteria. Cephalalgia. 30:560–6. DOI: 10.1111/j.1468-2982.2009.02010.x. PMID: 19740123.

31. Moskatel LS, Smirnoff L. 2022; Protracted headache after COVID-19: a case series of 31 patients from a tertiary headache center. Headache. 62:903–7. DOI: 10.1111/head.14337. PMID: 35670231. PMCID: PMC9348335.

32. Planchuelo-Gómez Á, García-Azorín D, Guerrero ÁL, Rodríguez M, Aja-Fernández S, de Luis-García R. 2023; Structural brain changes in patients with persistent headache after COVID-19 resolution. J Neurol. 270:13–31. DOI: 10.1007/s00415-022-11398-z. PMID: 36178541. PMCID: PMC9522538.

33. Yamani N, Olesen J. 2019; New daily persistent headache: a systematic review on an enigmatic disorder. J Headache Pain. 20:80. DOI: 10.1186/s10194-019-1022-z. PMID: 31307396. PMCID: PMC6734284.

34. Peng KP, Wang SJ. 2022; Update of new daily persistent headache. Curr Pain Headache Rep. 26:79–84. DOI: 10.1007/s11916-022-01005-1. PMID: 35076874. PMCID: PMC8787738.

35. Simmons AC, Bonner A, Giel A, Pezzano A, Rothner AD. 2022; Probable new daily persistent headache after COVID-19 in children and adolescents. Pediatr Neurol. 132:1–3. DOI: 10.1016/j.pediatrneurol.2022.04.009. PMID: 35598584. PMCID: PMC9045862.

36. Sampaio Rocha-Filho PA, Voss L. 2020; Persistent headache and persistent anosmia associated with COVID-19. Headache. 60:1797–9. DOI: 10.1111/head.13941. PMID: 32790179. PMCID: PMC7436496.

37. Dono F, Consoli S, Evangelista G, D'Apolito M, Russo M, Carrarini C, et al. 2021; New daily persistent headache after SARS-CoV-2 infection: a report of two cases. Neurol Sci. 42:3965–8. DOI: 10.1007/s10072-021-05444-3. PMID: 34264414. PMCID: PMC8280630.

38. Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. 2021; Toward a better understanding of persistent headache after mild COVID-19: three migraine-like yet distinct scenarios. Headache. 61:1277–80. DOI: 10.1111/head.14197. PMID: 34363619. PMCID: PMC8444902.

39. Li D, Rozen TD. 2002; The clinical characteristics of new daily persistent headache. Cephalalgia. 22:66–9. DOI: 10.1046/j.1468-2982.2002.00326.x. PMID: 11993616.

40. Prakash S, Saini S, Rana KR, Mahato P. 2012; Refining clinical features and therapeutic options of new daily persistent headache: a retrospective study of 63 patients in India. J Headache Pain. 13:477–85. DOI: 10.1007/s10194-012-0461-6. PMID: 22644215. PMCID: PMC3464463.

41. Evans RW. 2021; Primary non-continuous new daily persistent headache: seven cases and proposed diagnostic criteria. Cephalalgia Rep. 4:1–4. DOI: 10.1177/2515816321998349.

42. Fernández-de-Las-Peñas C, Gómez-Mayordomo V, García-Azorín D, Palacios-Ceña D, Florencio LL, Guerrero AL, et al. 2021; Previous history of migraine is associated with fatigue, but not headache, as long-term post-COVID symptom after severe acute respiratory SARS-CoV-2 infection: a case-control study. Front Hum Neurosci. 15:678472. DOI: 10.3389/fnhum.2021.678472. PMID: 34295230. PMCID: PMC8290894.

43. Magdy R, Elmazny A, Soliman SH, Elsebaie EH, Ali SH, Abdel Fattah AM, et al. 2022; Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case-control study. J Headache Pain. 23:101. DOI: 10.1186/s10194-022-01468-y. PMID: 35962348. PMCID: PMC9372973.

44. Vandenbussche N, Laterza D, Lisicki M, Lloyd J, Lupi C, Tischler H, et al. 2018; Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 19:50. DOI: 10.1186/s10194-018-0875-x. PMID: 30003412. PMCID: PMC6043466.